FrancophonIA/ELRC3.0 huggingface dataset:
English: The efficacy of hormonal contraceptives may be reduced during and for 28 days after administration of fosaprepitant.
Croatian: Djelotvornost hormonskih kontraceptiva može biti smanjena tijekom primjene i u razdoblju od 28 dana nakon primjene fosaprepitanta.
English: • if you are allergic to fosaprepitant, aprepitant, or to polysorbate 80 or any of the other ingredients (listed in section 6).
Croatian: • ako ste alergični na fosaprepitant, aprepitant, polisorbat 80 ili neki drugi sastojak ovog lijeka (naveden u dijelu 6).
English: All paediatric patients
Croatian: Svi pedijatrijski bolesnici
English: Fosaprepitant must not be used concurrently with pimozide, terfenadine, astemizole, or cisapride.
Croatian: Fosaprepitant se ne smije davati istodobno s pimozidom, terfenadinom, astemizolom niti cisapridom.
English: 5-HT3 antagonist
Croatian: 5-HT3 antagonisti
English: Aprepitant is highly protein bound, with a mean of 97 %.
Croatian: Aprepitant se u visokom postotku veže za proteine, u prosjeku 97%.
English: Control regimen (N =498) **
Croatian: Kontrolni režim (N =498) **
English: Since fosaprepitant is converted to aprepitant, those adverse reactions associated with aprepitant are expected to occur with fosaprepitant.
Croatian: Budući da se fosaprepitant pretvara u aprepitant, nuspojave povezane s aprepitantom očekuju se i pri primjeni fosaprepitanta.
English: There are some medicines that should not be taken with IVEMEND (such as pimozide, terfenadine, astemizole, and cisapride) or that require a dose adjustment (see also ‘Do not use IVEMEND').
Croatian: Neki se lijekovi ne smiju uzimati s lijekom IVEMEND (npr. pimozid, terfenadin, astemizol i cisaprid), ili je potrebno prilagoditi njihovu dozu (također vidjeti dio „Nemojte uzimati IVEMEND“).
English: Corticosteroids
Croatian: Kortikosteroidi
English: Because of the antiemetic activity of aprepitant, emesis induced by a medicinal product may not be effective.
Croatian: Budući da aprepitant djeluje antiemetički, izazivanje povraćanja primjenom lijekova moglo bi biti neučinkovito.
English: How to use IVEMEND
Croatian: Kako primjenjivati IVEMEND
English: Effect of fosaprepitant on the pharmacokinetics of other active substances CYP3A4 inhibition
Croatian: Djelovanje fosaprepitanta na farmakokinetiku drugih djelatnih tvari Inhibicija CYP3A4
English: The majority of severe ISRs, including thrombophlebitis and vasculitis, were reported with concomitant vesicant (e.g., anthracycline-based) chemotherapy administration, particularly when associated with extravasation.
Croatian: Većina teških reakcija na mjestu infuzije, uključujući tromboflebitis i vaskulitis, prijavljene su kod istodobne primjene kemoterapije vezikantom (bazirane na antraciklinu), osobito kada je povezana s ekstravazacijom.
English: , Mg including Hartman's and lactated Ringer's solutions.
Croatian: , Mg što uključuje i Hartmanovu otopinu i Ringerovu otopinu sa laktatom.
English: Additionally, concomitant administration with irinotecan should be approached with particular caution as the combination might result in increased toxicity.
Croatian: Posebnu pozornost treba obratiti pri istodobnoj primjeni s irinotekanom jer ona može uzrokovati pojačano toksično djelovanje irinotekana.
English: Co-administration with pimozide, terfenadine, astemizole or cisapride (see section 4.5).
Croatian: Istodobna primjena s pimozidom, terfenadinom, astemizolom ili cisapridom (vidjeti dio 4.5).
English: - Infusion site reactions (ISR) at or near the infusion site.
Croatian: - Reakcije na mjestu infuzije ili blizu mjesta infuzije.
English: Gently invert the bag 2-3 times.
Croatian: Nježno 2-3 puta preokrenite vrećicu.
English: The medicinal product must not be reconstituted or mixed with solutions for which physical and chemical compatibility has not been established (see section 6.2).
Croatian: Lijek se ne smije rekonstituirati niti miješati s otopinama za koje nije utvrđena fizikalna i kemijska kompatibilnost (vidjeti dio 6.2).
English: In the event of overdose, fosaprepitant should be discontinued and general supportive treatment and monitoring should be provided.
Croatian: U slučaju predoziranja, treba prekinuti primjenu fosaprepitanta, primijeniti uobičajene suportivne mjere liječenja i osigurati nadzor bolesnika.
English: Eye disorders conjunctivitis rare
Croatian: Poremećaji oka konjunktivitis rijetko
English: 2 mg/kg intravenously OR 2 mg/kg orally (EMEND oral suspension)
Croatian: 2 mg/kg intravenski ILI 2 mg/kg peroralno (EMEND oralna suspenzija)
English: After reconstitution and dilution: 24 hours at 25°C.
Croatian: Nakon rekonstitucije i razrjeđivanja: 24 sata na 25°C.
English: Maximum dose 80 mg
Croatian: Maksimalna doza 80 mg
English: Efficacy was based on evaluation of the following composite measures: complete response in both the overall and delayed phases and no vomiting in the overall phase.
Croatian: Ocjena djelotvornosti zasnivala se na temelju sljedećih skupnih mjera ishoda: potpunom odgovoru na liječenje tijekom cijelog razdoblja i u kasnijoj fazi te izostanku povraćanja tijekom cijelog razdoblja.
English: Hypersensitivity to the active substance or to polysorbate 80 or any of the other excipients listed in section 6.1.
Croatian: Preosjetljivost na djelatnu tvar ili na polisorbat 80 ili neku od pomoćnih tvari navedenih u dijelu 6.1.
English: The solution for infusion is given to you by a health care professional, such as a doctor or nurse, via an intravenous infusion (a drip) approximately 30 minutes before you start the chemotherapy treatment in adults or 60 - 90 minutes before you start the chemotherapy treatment in children and adolescents.
Croatian: Otopinu za infuziju dati će Vam zdravstvani radnik, liječnik ili medicinska sestra, intravenskom infuzijom (dripom, tj. kap po kap) približno 30 minuta prije početka kemoterapije ako ste odrasla osoba ili 60-90 minuta prije početka kemoterapije u djece i adolescenata.
English: Intravenous administration in paediatric patients aged 6 months and older is recommended through a central venous catheter and should be administered over 30 minutes in patients aged 12 years and older or over 60 minutes in patients less than 12 years of age (See section 6.6).
Croatian: U pedijatrijskih bolesnika u dobi od 6 mjeseci i starijih preporučuje se intravenska primjena kroz centralni venski kateter i to tijekom 30 minuta u bolesnika u dobi od 12 godina i starijih ili tijekom 60 minuta u bolesnika mlađih od 12 godina (vidjeti dio 6.6).
English: The total exposure of CYP3A4 substrates may increase up to 2-fold on Days 1 and 2 after coadministration with a single 150 mg fosaprepitant dose.
Croatian: Ukupna izloženost supstrata CYP3A4 može narasti do dva puta 1. i 2. dana nakon istodobne primjene s jednokratnom dozom fosaprepitanta od 150 mg.
English: The 3-day oral aprepitant regimen resulted in an about 30-35 % reduction in AUC of CYP2C9 substrates and up to a 64 % decrease in ethinyl estradiol trough concentrations.
Croatian: Trodnevni režim liječenja peroralnim aprepitantom rezultirao je smanjenjem AUC supstrata CYP2C9 za 30-35% te padom najniže koncentracije etinilestradiola za do 64%.
English: Depending on the chemotherapy treatment, there are two ways IVEMEND may be given: IVEMEND is given only on Day 1 (single day of chemotherapy) IVEMEND is given on Day 1, 2, and 3 (single or multiple days of chemotherapy) o Oral formulations of aprepitant may be prescribed on Days 2 and 3 instead of IVEMEND.
Croatian: Ovisno o kemoterapijskom liječenju, IVEMEND se može davati na dva načina: IVEMEND se daje samo 1. dana (jednodnevna kemoterapija) IVEMEND se daje 1., 2. i 3. dana (jednodnevna ili višednevna kemoterapija) o umjesto lijeka IVEMEND mogu se propisati peroralni pripravci aprepitanta 2. i 3. dana.
English: Intravenous administration in adults occurs preferably through a running intravenous infusion over 20-30 minutes.
Croatian: Odraslima ga je najbolje primijeniti intravenskom infuzijom u trajanju od 20-30 minuta.
English: Effect of other medicinal products on the pharmacokinetics of aprepitant resulting from administration of fosaprepitant 150 mg
Croatian: Djelovanje drugih lijekova na farmakokinetiku aprepitanta kao rezultat primjene fosaprepitanta 150 mg
English: Therefore, the recommendations for use of IVEMEND with other medicinal products in paediatric patients are based upon adult data from fosaprepitant and aprepitant studies.
Croatian: Stoga se preporuke za primjenu lijeka IVEMEND s drugim lijekovima u pedijatrijskih bolesnika temelje na podacima prikupljenima u kliničkim ispitivanjima fosaprepitanta i aprepitanta u odraslih.
English: Immediate hypersensitivity reactions including flushing, erythema, dyspnoea, and anaphylaxis/anaphylactic shock have occurred during or soon after infusion of fosaprepitant.
Croatian: Trenutne reakcije preosjetljivosti uključujući navale crvenila, eritem, dispneju i anafilaksiju/anafilaktički šok javile su se tijekom ili ubrzo nakon infuzije fosaprepitanta.
English: Dexamethasone should also be administered in the evenings on Days 3 and 4.
Croatian: Deksametazon treba dati i 3. i 4. dana navečer.
English: IVEMEND is used in adults, adolescents, and children aged 6 months or older in combination with other medicines to prevent nausea and vomiting caused by chemotherapy (cancer treatment) that is a strong or moderate trigger of nausea and vomiting.
Croatian: IVEMEND se koristi u odraslih bolesnika, adolescenata i djece u dobi od 6 mjeseci ili starije zajedno s drugim lijekovima za sprječavanje mučnine i povraćanja uzrokovanih kemoterapijom (liječenje raka) koja je jaki ili umjereni okidač mučnine i povraćanja.
English: In the performed safety pharmacology and repeated dose toxicity studies with dogs, fosaprepitant Cmax and aprepitant AUC values were up to 3 times and 40 times, respectively, higher than clinical values.
Croatian: U provedenim ispitivanjima sigurnosne farmakologije i toksičnosti ponovljenih doza na psima, Cmax fosaprepitanta bio je do 3 puta viši, a AUC aprepitanta 40 puta viši od kliničkih vrijednosti.
English: In clinical studies, various formulations of fosaprepitant have been administered to a total of 2,687 adults including 371 healthy subjects and 2,084 patients, and 199 children and adolescents with chemotherapy induced nausea and vomiting (CINV).
Croatian: U kliničkim ispitivanjima, fosaprepitant je u različitim formulacijama primijenjen u ukupno 2687 odraslih ispitanika, uključujući 371 zdravih ispitanika i 2084 bolesnika, te 199 djece i adolescenata s mučninom i povraćanjem izazvanim kemoterapijom (engl. chemotherapy induced nausea and vomiting, CINV).
English: Prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults and paediatric patients aged 6 months and older.
Croatian: Sprječavanje mučnine i povraćanja povezanih s jako i umjereno emetogenom kemoterapijom raka u odraslih i pedijatrijskih bolesnika u dobi od 6 mjeseci i starijih.
English: It is anticipated that IVEMEND would cause less or no greater induction of CYP2C9, CYP3A4, and glucuronidation than that caused by the administration of the 3-day oral aprepitant regimen, for which a transient induction with its maximum effect 6-8 days after first aprepitant dose has been observed.
Croatian: Pretpostavlja se da će IVEMEND uzrokovati manju ili ne veću indukciju CYP2C9, CYP3A4 i glukuronidacije od one koju uzrokuje trodnevni režim liječenja peroralnim aprepitantom, kod kojeg je opažena prolazna indukcija s najjačim učinkom 6-8 dana nakon prve doze aprepitanta.
English: Hepatic impairment: Fosaprepitant is metabolized in various extrahepatic tissues; therefore hepatic impairment is not expected to alter the conversion of fosaprepitant to aprepitant.
Croatian: Oštećenje funkcije jetre: Fosaprepitant se razgrađuje u različitim tkivima izvan jetre; stoga se ne očekuje da će oštećenje funkcije jetre utjecati na njegovu pretvorbu u aprepitant.
English: Determine the volume to be administered from this prepared infusion bag, based on the recommended dose (see section 4.2).
Croatian: Odredite volumen koji će se primijeniti iz ove pripremljene vrećice za infuziju na temelju preporučene doze (vidjeti dio 4.2).
English: IVEMEND should not be administered intramuscularly or subcutaneously (see section 5.3).
Croatian: IVEMEND se ne smije primijeniti intramuskularno niti supkutano (vidjeti dio 5.3).
English: 245.3 mg of fosaprepitant dimeglumine (equivalent to 150 mg fosaprepitant) to aprepitant, 23.9 mg of phosphoric acid and 95.3 mg of meglumine are liberated.
Croatian: 245,3 mg fosaprepitantdimeglumina (što odgovara 150 mg fosaprepitanta) u aprepitant, oslobađa se 23,9 mg fosforne kiseline i 95,3 mg meglumina.
English: IVEMEND must be reconstituted and then diluted prior to administration.
Croatian: IVEMEND se prije primjene mora rekonstituirati, a zatim i razrijediti.
English: Dexamethasone: The oral dexamethasone dose should be reduced by approximately 50 % when coadministered with fosaprepitant (see section 4.2).
Croatian: Deksametazon: uobičajenu dozu peroralnog deksametazona treba sniziti za približno 50% primjenjuje li se istodobno s fosaprepitantom (vidjeti dio 4.2).
English: A summary of the primary and secondary endpoints is shown in Table 7.
Croatian: U Tablici 7 prikazane su sažete primarne i sekundarne mjere ishoda.
English: ** Dexamethasone should be administered 30 minutes prior to chemotherapy treatment on Day 1.
Croatian: ** Deksametazon se mora primijeniti 30 minuta prije kemoterapijskog liječenja 1. dana.
English: Induction
Croatian: Indukcija
English: The pharmacokinetics of aprepitant is non-linear across the clinical dose range.
Croatian: Farmakokinetika aprepitanta je nelinearna u rasponu kliničkih doza.
English: 12 - 17 years old 115mg, 80mg, 80mg
Croatian: 115 mg, 80 mg, 80 mg
English: 150 mg intravenously none none none
Croatian: IVEMEND 150 mg intravenski ništa ništa ništa
English: After reconstitution and dilution 1 ml of solution contains 1 mg fosaprepitant (1 mg/ml) (see section 6.6).
Croatian: Nakon rekonstitucije i razrjeđivanja, 1 ml otopine sadrži 1 mg fosaprepitanta (1 mg/ml) (vidjeti dio 6.6).
English: • with medicines containing pimozide (used to treat psychiatric illnesses), terfenadine and astemizole (used for hay fever and other allergic conditions), cisapride (used for treating digestive problems).
Croatian: • s lijekovima koji sadrže pimozid (za liječenje psihijatrijskih bolesti), terfenadin i astemizol (za peludnu hunjavicu i druge alergijske tegobe) te cisaprid (za poremećaje probavnog sustava).
English: After reconstitution and dilution, chemical and physical in-use stability has been demonstrated for 24 hours at 25°C.
Croatian: Nakon rekonstitucije i razrjeđivanja, dokazana kemijsko fizikalna stabilnost lijeka u primjeni iznosi 24 sata pri 25°C.
English: The powder is contained in a clear glass vial with a rubber stopper and an aluminum seal with a grey plastic flip off cap.
Croatian: Prašak se nalazi u prozirnoj staklenoj bočici s gumenim čepom, aluminijskim prstenom i sivom plastičnom flip off kapicom.
English: Following a single 150 mg fosaprepitant dose, a transient moderate increase for two days possibly followed by a mild decrease in exposure of immunosuppressants metabolised by CYP3A4 (e.g. cyclosporine, tacrolimus, everolimus and sirolimus) is expected.
Croatian: Nakon jednokratne doze fosaprepitanta od 150 mg očekuje se prolazni umjereni porast (moguće tijekom dva dana), a nakon njega blagi pad izloženosti imunosupresiva koji se metaboliziraju putem CYP3A4 (npr. ciklosporina, takrolimusa, everolimusa i sirolimusa).
English: Caution is advised and additional monitoring may be appropriate in patients receiving medicinal products metabolized primarily or partly by CYP3A4 (see section 4.4).
Croatian: Potrebna je posebna pozornost i dodatni nadzor bolesnika koji primaju lijekove koji se primarno ili djelomično metaboliziraju putem CYP3A4 (vidjeti dio 4.4).
English: In laboratory animals, fosaprepitant in non-commercial formulations caused vascular toxicity and hemolysis at concentrations below 1 mg/ml and higher, dependent on the formulation.
Croatian: Fosaprepitant primijenjen kod laboratorijskih životinja u farmaceutskim oblicima koji nisu bili namijenjeni tržištu, uzrokovao je vaskularnu toksičnost i hemolizu pri koncentracijama nižim od 1 mg/ml naviše, ovisno o farmaceutskom obliku u kojem je primijenjen.
English: Paediatric patients 2 to less than 12 years
Croatian: Pedijatrijski bolesnici u dobi od 2 do manje od 12 godina
English: These studies did not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, parturition or postnatal development (see section 5.3).
Croatian: Ta istraživanja nisu ukazala na izravno ili neizravno štetno djelovanje na trudnoću, embriofetalni razvoj, okot niti postnatalni razvoj (vidjeti dio 5.3).
English: In patients with ESRD undergoing haemodialysis, the AUC0- of total aprepitant decreased by 42 % and Cmax decreased by 32 %.
Croatian: U ispitanika s ESRD-om na hemodijalizi, AUC0-∞ ukupnog aprepitanta snizio se za 42%, a Cmax za 32%.
English: Tell your doctor about any other medicines or herbal medicines you are taking, have recently taken, or might take.
Croatian: Obavijestite svog liječnika ako uzimate, nedavno ste uzeli ili biste mogli uzeti bilo koje druge lijekove, uključujući i biljne lijekove.
English: Do not administer IVEMEND as a bolus injection or undiluted solution.
Croatian: IVEMEND se ne smije primijeniti kao bolus injekcija niti kao nerazrijeđena otopina.
English: IVEMEND is incompatible with any solutions containing divalent cations (e.g., Ca
Croatian: IVEMEND je inkompatibilan sa svim otopinama koje sadrže dvovalentne katione (npr. Ca
English: • Volume to administer (ml) = recommended dose (mg/kg) x weight (kg) o Note: Do not exceed maximum doses (see section 4.2).
Croatian: • volumen koji će se primijeniti (ml) = preporučena doza (mg/kg) x tjelesna težina (kg) o Napomena: Maksimalne doze ne smiju se prekoračiti (vidjeti dio 4.2).
English: Dexamethasone should be administered 30 minutes prior to chemotherapy treatment on Day 1 and in the morning on Days 2 to 4.
Croatian: Deksametazon treba dati 1. dana liječenja 30 minuta prije kemoterapije, i 2. do 4. dana ujutro.
English: The frequency categories given in the table are based on the studies in adults; the observed frequencies in the paediatric studies were similar or lower, unless shown in the table.
Croatian: Kategorije učestalosti navedene u tablici temelje se na ispitivanjima u odraslih; opažene učestalosti u pedijatrijskim ispitivanjima bile su slične ili niže, osim ako su prikazane u tablici.
English: It is anticipated that fosaprepitant would cause less or no greater induction of CYP2C9, CYP3A4 and glucuronidation than that caused by the administration of oral aprepitant.
Croatian: Pretpostavlja se da će fosaprepitant uzrokovati manju ili ne veću indukciju CYP2C9, CYP3A4 i glukuronidaciju od one koju uzrokuje peroralni aprepitant.
English: At the end of the follow-up period (post-dose day 8), up to slight local subacute inflammation was noted following paravenous and intramuscular administration and additional up to moderate focal muscle degeneration/necrosis with muscle regeneration following intramuscular administration.
Croatian: Na kraju razdoblja praćenja (8 dana nakon posljednje doze), blaga lokalna subakutna upala zabilježena je nakon paravenske i intramuskularne primjene; također je nakon intramuskularne primjene lijeka zabilježena umjerena fokalna mišićna degeneracija/nekroza s regeneracijom mišića.
English: IVEMEND should be used with caution in these patients (see sections 4.4 and 5.2).
Croatian: Tim bolesnicima IVEMEND treba davati uz oprez (vidjeti dijelove 4.4 i 5.2).
English: In human washed blood cells also evidence of hemolysis was found with non-commercial formulations at fosaprepitant concentrations of 2.3 mg/ml and higher, although tests in human whole blood were negative.
Croatian: Hemoliza je također utvrđena u ljudskim ispranim krvnim stanicama nakon primjene fosaprepitanta u oblicima koji nisu namijenjeni tržištu, i to pri koncentraciji fosaprepitanta od 2,3 mg/ml naviše, iako su testovi s ljudskom punom krvlju bili negativni.
English: Instructions of how to reconstitute and dilute IVEMEND 150 mg
Croatian: Upute za rekonstituciju i razrjeđivanje lijeka IVEMEND 150 mg:
English: Some less common ADRs in the adult population were not observed in the paediatric studies.
Croatian: Neke manje česte nuspojave u odrasle populacije nisu bile opažene u pedijatrijskim ispitivanjima.
English: Vascular disorders flushing, thrombophlebitis (predominantly, infusion-site thrombophlebitis)
Croatian: Krvožilni poremećaji navale crvenila, tromboflebitis (pretežno tromboflebitis na mjestu infuzije)
English: See the summary of product characteristics for EMEND capsules and EMEND powder for oral suspension for complete clinical information regarding studies performed with oral aprepitant.
Croatian: Pročitajte sažetak opisa svojstava lijeka za EMEND kapsule i EMEND prašak za oralnu suspenziju radi potpunih kliničkih informacija o ispitivanjima provedenima s peroralnim aprepitantom.
English: See the product information for the selected 5-HT3 antagonist for appropriate dosing information Dexamethasone should be administered 30 minutes prior to chemotherapy treatment on Day 1.
Croatian: Za pravilno doziranje vidjeti uputu o lijeku odabranih 5-HT3 antagonista Deksametazon treba dati 1. dana liječenja 30 minuta prije kemoterapije.
English: It should be taken into account that some people get dizzy and get sleepy after using IVEMEND.
Croatian: Treba imati na umu da IVEMEND u nekih ljudi izaziva omaglicu i pospanost.
English: Discard any remaining solution and waste material.
Croatian: Preostalu otopinu ili otpadni materijal bacite.
English: Co-administration with warfarin (a CYP2C9 substrate) In patients on chronic warfarin therapy, the International Normalised Ratio (INR) should be monitored closely for 14 days following the use of fosaprepitant (see section 4.5).
Croatian: Istodobna primjena s varfarinom (supstratom CYP2C9) U bolesnika na kroničnom liječenju varfarinom treba strogo nadzirati međunarodni normalizirani omjer (INR) tijekom 14 dana nakon primjene fosaprepitanta (vidjeti dio 4.5).
English: These fertility studies did not indicate direct or indirect harmful effects with respect to mating performance, fertility, embryonic/foetal development, or sperm count and motility (see section 5.3).
Croatian: Ta istraživanja nisu ukazala na izravno ili neizravno štetno djelovanje na učinkovitost parenja, plodnost, embriofetalni razvoj, broj i pokretljivost spermija (vidjeti dio 5.3).
English: The safety profile of the 3-day IV fosaprepitant regimen in paediatric patients is expected to be similar to that of the 1-day fosaprepitant regimen as the low daily trough levels do not significantly increase the exposures on subsequent days.
Croatian: Očekuje se da je sigurnosni profil trodnevnog režima intravenskim fosaprepitantom u pedijatrijskih bolesnika sličan sigurnosnom profilu jednodnevnog režima fosaprepitantom budući da niska vrijednost najniže dnevne razine lijeka ne povećava značajno izloženost tijekom sljedećih dana.
English: Immunosuppressants
Croatian: Imunosupresivi
English: In humans, fosaprepitant administered intravenously was rapidly converted to aprepitant within 30 minutes following the end of infusion.
Croatian: U ljudi, intravenski se fosaprepitant pretvorio u aprepitant unutar 30 minuta od završetka infuzije.
English: EMEND capsules or EMEND for oral suspension may be used on Days 2 and 3 instead of IVEMEND, as shown in
Croatian: Umjesto lijeka IVEMEND, 2. i 3. dana mogu se primijeniti EMEND kapsule ili EMEND oralna suspenzija, kako je prikazano u tablici 3.
English: IVEMEND contains the active substance fosaprepitant which is converted to aprepitant in your body.
Croatian: IVEMEND sadrži djelatnu tvar fosaprepitant, koji se u organizmu pretvara u aprepitant.
English: Aprepitant is excreted in the milk of lactating rats after intravenous administration of fosaprepitant as well as after oral administration of aprepitant.
Croatian: Aprepitant se izlučuje u mlijeko štakorica nakon intravenske primjene fosaprepitanta i nakon peroralne primjene aprepitanta.